Published in Pancreatology on January 01, 2002
Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) (2004) 1.03
Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg (2013) 0.99
Survival from cancer of the pancreas in England and Wales up to 2001. Br J Cancer (2008) 0.91
No-touch isolation techniques for pancreatic cancer. Surg Today (2016) 0.76
Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience. BMC Cancer (2016) 0.75
Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk? Wien Klin Wochenschr (2016) 0.75
[New aspects of surgery for pancreatic cancer. Principles, results and evidence]. Pathologe (2012) 0.75
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (2011) 4.06
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet (2011) 3.54
IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology (2002) 3.48
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg (2008) 2.82
Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol (2004) 2.82
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol (2007) 2.80
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
Biology and management of pancreatic cancer. Gut (2007) 2.53
Fatty acid ethyl esters cause pancreatic calcium toxicity via inositol trisphosphate receptors and loss of ATP synthesis. Gastroenterology (2006) 2.23
Reactive oxygen species induced by bile acid induce apoptosis and protect against necrosis in pancreatic acinar cells. Gastroenterology (2011) 2.06
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg (2008) 1.93
Direct activation of cytosolic Ca2+ signaling and enzyme secretion by cholecystokinin in human pancreatic acinar cells. Gastroenterology (2008) 1.89
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol (2003) 1.83
Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. Ann Surg (2010) 1.79
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer (2004) 1.68
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut (2007) 1.68
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet (2012) 1.63
New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol (2012) 1.57
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res (2004) 1.44
Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. Proc Natl Acad Sci U S A (2004) 1.42
Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell (2012) 1.40
Scientific data from clinical trials: investigators' responsibilities and rights. Surg Endosc (2002) 1.39
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer (2011) 1.38
Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg (2002) 1.35
Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg (2008) 1.26
Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology (2009) 1.22
Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol Cell Proteomics (2010) 1.21
Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.16
Acute pancreatitis and organ failure: pathophysiology, natural history, and management strategies. Curr Gastroenterol Rep (2004) 1.15
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics (2003) 1.14
Signal transduction, calcium and acute pancreatitis. Pancreatology (2003) 1.12
Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol (2002) 1.08
The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery (2008) 1.07
The value of source data verification in a cancer clinical trial. PLoS One (2012) 1.07
Pancreatic pseudocyst in chronic pancreatitis: endoscopic and surgical treatment. Dig Surg (2003) 1.05
A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics (2009) 1.04
Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res (2009) 1.02
Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat (2005) 1.02
Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res (2012) 1.01
Preprotachykinin-A gene deletion protects mice against acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol (2003) 1.00
Pancreatic cancer susceptibility loci and their role in survival. PLoS One (2011) 0.98
Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut (2010) 0.98
CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol (2003) 0.97
Management of pancreatic masses. Pancreas (2005) 0.97
Expression patterns of protein kinase C isoenzymes are characteristically modulated in chronic pancreatitis and pancreatic cancer. Am J Clin Pathol (2003) 0.96
Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis (2010) 0.96
Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. Pancreas (2002) 0.96
Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis (2012) 0.95
Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol (2011) 0.94
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother (2013) 0.94
The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Pract Res Clin Gastroenterol (2006) 0.94
New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol (2002) 0.94
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut (2009) 0.92
MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation. Am J Physiol Gastrointest Liver Physiol (2002) 0.92
Adjuvant therapy in pancreatic cancer. Dig Dis (2010) 0.92
Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med (2007) 0.91
Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology (2009) 0.90
Scientific data from clinical trials: investigators' responsibilities and rights. World J Surg (2002) 0.89
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer (2008) 0.88
Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer (2009) 0.88
Trypsinogen mutations in pancreatic disorders. Endocrinol Metab Clin North Am (2006) 0.88
New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol (2008) 0.87
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med (2004) 0.87
RNASEL germline variants are associated with pancreatic cancer. Int J Cancer (2005) 0.86
ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep (2013) 0.86
Genetics and prevention of pancreatic cancer. Cancer Control (2004) 0.85
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer (2014) 0.85
Prognostic markers in acute pancreatitis. Expert Rev Mol Diagn (2014) 0.84
Describing peripancreatic collections in severe acute pancreatitis using morphologic terms: an international interobserver agreement study. Pancreatology (2008) 0.84
Does infected pancreatic necrosis require immediate or emergency debridement? Pancreas (2006) 0.82
Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol (2006) 0.82
Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Cancer Epidemiol Biomarkers Prev (2012) 0.81
Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One (2013) 0.81
Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology (2011) 0.81
Cationic trypsinogen mutations and pancreatitis. Gastroenterol Clin North Am (2004) 0.81
Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother (2006) 0.81
Surgical oncology: PBD-better stents in specialized centers are needed. Nat Rev Clin Oncol (2010) 0.79
Analysis of serum proteins by LC-MS/MS. Methods Mol Biol (2010) 0.79
Cationic trypsinogen mutations and pancreatitis. Clin Lab Med (2005) 0.79
Scientific data from clinical trials: investigators' responsibilities and rights. Arch Surg (2002) 0.79
Severe acute pancreatitis is related to increased early urinary levels of the activation Peptide of pancreatic phospholipase A(2). Pancreatology (2002) 0.79
Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surg Oncol Clin N Am (2004) 0.79
A preoperative prognostic score for resected pancreatic and periampullary neuroendocrine tumours. Pancreatology (2009) 0.78
Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis. Ann Surg (2016) 0.78
Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer. Nat Clin Pract Oncol (2008) 0.78
Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg (2016) 0.77
No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett (2004) 0.77
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg (2016) 0.75
Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal". Drugs (2007) 0.75
Compartments that cause the real damage in severe acute pancreatitis. Am J Respir Crit Care Med (2003) 0.75
Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evid (2007) 0.75
Laparoscopy is still necessary in the assessment of peri-ampullary neoplasia. Pancreatology (2004) 0.75
Scientific data from clinical trials: investigators' responsibilities and rights. J Vasc Surg (2002) 0.75